Main Menu

Video: Better experimental models to help drugs succeed in clinical trials

Dr Amanda Swain leads the ICR’s Tumour Profiling Unit, which is a state-of-the-art centre designed to accelerate progress towards precision medicine.

Unfortunately, the vast majority of experimental cancer drugs entering phase I clinical trials will not make it all the way through to the market. One way to improve on these poor success rates is to develop better models for evaluating the effectiveness of potential new treatments before they move into clinical trials.

Dr Swain’s team is developing xenografts derived from tumour biopsies collected from patients who are undergoing clinical trials. Using these more relevant models for preclinical testing will help ensure that only the most promising experimental drugs move into human studies – enabling time and resources to be focussed on the treatments that are most likely to succeed.

Dr Swain is open to partnering with pharmaceutical companies who are looking to carry out pre-clinical testing of novel drugs in patient-derived xenograft models. This innovative approach also opens exciting opportunities to screen for new treatment combinations that can help overcome drug resistance.

Watch more videos of our researchers

Working with pharmaceutical companies

Dr Marco Gerlinger talking about working with pharmaceutical companies

Dr Marco Gerlinger's Translational Oncogenomics Team are keen to develop new partnerships to continue their work, and to access drugs that could reverse the resistance mechanisms that the team has identified so far.


New partnerships in cancer epigenetics

Professor Jessica Downs

Our Epigenetics and Genome Stability team, led by Professor Jessica Downs, is working on a variety of research programmes that could be developed in collaboration with commercial partners.


Sharing experience with industry partners

Dr Paul Huang

Our Molecular and Systems Oncology Team, led by Dr Paul Huang, is keen to collaborate with industry partners on a number of projects on biochemistry, computational modelling, molecular pathology and proteomics.


Collaborating with commercial partners

Dr Anguraj Sadanandam

Our Systems and Precision Cancer Medicine team, led by Dr Anguraj Sadanandam, is investigating ways to stratify tumours based on their genetic and clinical diversity.


Exploring new opportunities for collaborative working

Professor Uwe Oelfke

Professor Uwe Oelfke, Deputy Head of the Division of Radiotherapy and Imaging, is keen to explore new opportunities for collaborative working with industry.


The benefits of partnering with industry

Dr Igor Vivanco

Our Molecular Addictions team, led by Dr Igor Vivanco, is working on a variety of projects that could be developed in collaboration with commercial partners.


Connections newsletter

Sign up to our new quarterly newsletter for updates on our Business and Innovation Office and news about working with industry.